1. Medtech Insight
  2. >>Market Access

Front Line Medical Counts On Fast UK Access For COBRA-OS REBOA Device

Aortic Occlusion Device Maker Plans To Capitalize On UK Prehospital System

 
• By Natasha Barrow

The UK's established emergency care prehospital system potentially opens up a faster route to market for Front Line Medical Technologies's aortic occlusion device, COBRA-OS. Asha Parekh, Front Line CEO, talks to Medtech Insight about the company's different strategic approach to UK market access in comparison to North America.

London, UK
Front Line Medical Technologies Launches COBRA-OS REBOA Device In The UK (Shutterstock)

Front Line Medical Technologies is approaching the UK with a different market access strategy in comparison to that for North America in the launch of the company’s aortic occlusion device, said Asha Parekh, Front Line Medical Technologies’ CEO.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

 
• By Natasha Barrow

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.

Diagnostics Are Essential, But How Can Companies Ensure A Fair Price?

 
• By Barnaby Pickering

Biotech and pharma are increasingly clear about one thing: They need diagnostics. But with prices suppressed, how have diagnostics companies proven their utility without going under?

European Medicine Agency’s CHMP Qualifies First AI Tool For Use In Clinical Trials

 
• By Natasha Barrow

With the support of AIM-MASH AI Assist only one pathologist is needed to reliably make a histology assessment of inflammatory liver disease to decide whether patients should be included in MASH clinical trials.

Boston Scientific Targets Multi-Billion Hypertension Market With SoniVie Acquisition

 
• By Natasha Barrow

Boston Scientific has entered the multi-billion hypertension treatment market with the acquisition of Israel-based startup SoniVie, developer of the TIVUS intravascular ultrasound system for the treatment of high blood pressure by artery nerve ablation.

More from Strategy